Mandate

Vinge advises Bridgepoint in conjunction with an investment in FCG

January 25, 2018

Vinge has advised Bridgepoint Development Capital in conjunction with the entry into of a partnership in FCG Holding Sverige AB.

FCG Holding Sverige AB is one of the Nordic region’s leading suppliers of specialist services within risk management, compliance, finance and capital management, financial law and corporate governance, with a focus on the financial sector.

The transaction is conditional upon approval by the Swedish Financial Supervisory Authority.

Vinge’s team primarily consisted of partner Daniel Rosvall together with associates Samra Baytar, Michaela Cronemyr, Christina Odengran and Caroline Krassén. Malin Haag and Carolina Sandell provided advice in connection with the notification to, and approval from, the Swedish Financial Supervisory Authority.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024